Last updated: September 22, 2026
FDA reviewers posted briefing documents for Grail’s September 23 Galleri panel with no outstanding questions on analytical performance, study design, or primary safety, per Reuters. Grail shares closed up 33.7% at $107.97. Telix agreed to buy ITM for $1.65 billion upfront, and Novo Nordisk ADRs fell 8.0% on its Capital Markets Day.
This page covers the primary documents, deal terms, and market closes behind Monday, September 21, 2026, ahead of Wednesday’s Galleri advisory committee meeting.
What did the FDA’s briefing documents say about Grail’s Galleri test?
According to Reuters, FDA staff raised no major concerns about the accuracy or safety of Galleri, writing that the agency has “no outstanding questions for the external panel on analytical performance, study design and the primary safety analyses of Galleri.” Endpoints News characterized the documents as neutral.
The documents posted Monday, two days before the meeting, after a weekend in which the meeting page carried nothing beyond two conflict of interest waivers. The only substantive question FDA reviewers put to the panel, per Reuters, is whether the evidence supports characterizing Galleri as an “early detection” test. That is not a technicality. Galleri is a blood based multi cancer early detection (MCED) test, and the “early detection” claim is the label language on which screening positioning and eventual reimbursement rest.
One sourcing note: multiple outlets (Reuters, STAT, Endpoints News) reported and characterized the documents on Monday. Our own fetch of the FDA meeting page at roughly 8:10 pm Pacific on Monday still listed only the two waiver PDFs, so the characterizations above are attributed to those outlets rather than quoted from a document we retrieved directly.
Context, attributed to Reuters: Grail shares had fallen more than 20% since February after disappointing UK trial results, and Galleri generated $136.8 million in US revenue in 2025 while selling as a laboratory developed test without FDA approval. Piper Sandler analyst David Westenberg called the documents “constructive for Grail” and said he anticipates “a favorable vote.”
What happens at the September 23 advisory committee meeting?
The Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee meets Wednesday, September 23, from 9:00 am to 6:00 pm ET at FDA’s White Oak campus, in hybrid format with a public YouTube webcast, to review the first premarket approval application for an MCED test.
The panel is expected to vote on safety and benefit, per Endpoints News. The docket is FDA-2026-N-8004. The FDA is not obliged to follow its advisory committees, but it often does, and an approval would be the first for any multi cancer early detection test. The vote has not happened, and nothing in this page should be read as an outcome. We will carry the vote count in Thursday’s edition.
What are the terms of Telix’s acquisition of ITM?
Telix Pharmaceuticals agreed to acquire ITM Isotope Technologies Munich SE for US$1.65 billion upfront on a cash free, debt free basis, plus up to US$700 million in contingent payments tied to ITM-11 approvals and sales. The announcement is dated September 21 from Melbourne, Indianapolis, and Munich.
| Component | Value | Detail |
|---|---|---|
| Equity consideration | US$1.25 billion | 105.8 million Telix shares issued at US$11.841 per share |
| Net debt assumed | US$302 million | Part of the US$1.65 billion upfront |
| Management rollover and expenses | US$96 million | Part of the US$1.65 billion upfront |
| Regulatory milestones | Up to US$250 million | Per Fierce Biotech: US$100 million for FDA approval of ITM-11 in GEP-NETs by end 2027, US$100 million for a second GEP-NET indication by end 2030, US$50 million for lung NETs by end 2031 |
| Sales milestones | Up to US$450 million | Three times ITM-11 net global sales in excess of US$150 million in 2030 |
| Total potential | Up to US$2.35 billion | Our arithmetic: US$1.65 billion upfront plus US$700 million contingent |
ITM-11 is 177Lu-edotreotide, a radioligand therapy for gastroenteropancreatic neuroendocrine tumors. The Phase 3 COMPETE trial is complete, the COMPOSE expansion study is fully enrolled with an interim analysis expected in the first half of 2027, and the program is under FDA review after what STAT described as a surprise FDA rejection earlier this cycle. ITM is also the only producer of globally scaled commercial grade lutetium-177, with 15 year exclusive access to Bruce Power’s nuclear reactors in Canada, and generated US$273 million in 2025 revenue with a 40% compound annual growth rate from 2021 to 2025, per the release. The companies project unaudited pro forma 2026 combined revenue and income exceeding US$1.3 billion.
The deal is expected to close by the end of 2026, subject to an extraordinary general meeting of Telix shareholders expected in November 2026 and regulatory clearances. Telix’s Nasdaq listed shares closed at $11.31 Monday, down 10.2% from Friday’s $12.59 close (our arithmetic), and below the US$11.841 at which the equity consideration was struck.
What did Novo Nordisk announce at its 2026 Capital Markets Day?
At its Capital Markets Day in London on Monday, Novo Nordisk set a target of at least five multi blockbusters by 2030 with combined sales above DKK 150 billion, described by CEO Mike Doustdar as risk adjusted, and unveiled a Consumer Rx platform. Novo ADRs fell 8.0%.
All figures in this section are company statements at the investor event as reported by Fierce Pharma; we did not retrieve a primary document Monday night.
| Announcement | Detail |
|---|---|
| Blockbuster target | At least five multi blockbusters by 2030; combined sales above DKK 150 billion (roughly $23 billion, Fierce conversion) in less than 10 years, risk adjusted |
| Consumer Rx | New platform for prescription medicines with strong consumer demand; immune mediated inflammatory disease, pain, addiction, women’s and men’s health; explicitly not OTC |
| Manufacturing | Capacity to serve 10 million patients by 2030, versus roughly 1.5 million oral Wegovy users today |
| US commercial | Expand Wegovy, stabilize Ozempic share, lean on the Medicare Part D bridge program offering GLP-1s at $50 per month through end 2027 |
| Workforce | 66,000 employees, down about 15% from 77,000 two years ago, after 9,000 announced layoffs and roughly 4,000 further departures |
| Pipeline | CagriSema FDA decision expected next year; zenagamtide, a long acting GLP-1 and amylin co agonist, in injection and pill forms; denecimig in hemophilia |
Fierce reported investor disappointment at the absence of M&A detail. Novo ADRs closed at $39.80 Monday against Friday’s $43.24, an 8.0% decline by our arithmetic. The company presents 44 abstracts at EASD in Milan next week, September 28 to October 2.
Where does the Medicaid MFN program stand ahead of September 30?
CMS said 40 states plus Puerto Rico have signed participation agreements for the GENEROUS Medicaid most favored nation model, that all 50 states plus DC and Puerto Rico applied, and that remaining states have until September 30 to sign, per the announcement reported by Fierce Healthcare.
The model runs five years from January 2026 and lets state Medicaid programs buy hundreds of drugs at prices aligned with what other countries pay. More than two dozen drugmakers agreed to participate in exchange for tariff relief and exemptions from a similar Medicare initiative, per The Hill as cited by Fierce Healthcare. Separately, Endpoints News reported Monday that Pfizer’s and Eli Lilly’s MFN contracts with HHS show both companies agreed to share revenue from raised foreign prices with the US government, a detail that reframes MFN as revenue capture rather than pure price cutting. That report is paywalled and the description above is attributed to it.
The September 30 signing deadline is the fourth dated event in what we have been calling deadline gauntlet week, landing one day after the September 29 Section 232 pharmaceutical tariff date.
What else moved in biotech, pharma, and medtech on September 21, 2026?
Monday also brought a first ever approval in ataxia-telangiectasia, a pivotal gene therapy win in X-linked retinitis pigmentosa, positive hives data against Xolair, orexin ADHD data, a Bayer divestment, two IPO filings, and a Mayo Clinic diagnostics venture.
IntraBio’s Aqneursa approved in ataxia-telangiectasia. The FDA expanded Aqneursa, first approved in 2024 for Niemann-Pick disease type C, into ataxia-telangiectasia, making it the first approved treatment for the disease anywhere, per Fierce Pharma. The Phase 3 IB1001-303 crossover study in 73 patients ages 4 to 50 showed close to a 2 point improvement on the SARA ataxia scale. Fierce reported a price of approximately $15,000 every one to two weeks; we found no pricing document.
Beacon Therapeutics’ pivotal XLRP win. Laruparetigene zovaparvovec (laru zova) met its endpoint in the Phase 2/3 VISTA study in X-linked retinitis pigmentosa: 24.1% of low dose and 31% of high dose patients read 15 or more additional letters under low light at 12 months, versus 0% of controls, per Fierce Biotech’s report of the data. The company plans to start and complete a rolling BLA before year end 2026.
Cue Biopharma’s CUE-221 beat Xolair on complete response in a China Phase 2. In a 145 subject chronic spontaneous urticaria study, complete hives resolution at week 12 ran 43 to 54% across CUE-221 dose cohorts versus 11% for placebo and 41% for the Xolair arm, with the high dose holding 60% response at week 28 versus 24% for Xolair, per Fierce Biotech’s report of the company’s release. A Phase 2b/3 is planned.
Alkermes reported first orexin agonist ADHD data. ALKS 7290 cut adult ADHD investigator symptom scores by an average of 14 points at 20 mg and 19 points at 50 mg in a 50 adult Phase 1b over two weeks, per Fierce Biotech’s report of the company announcement. A Phase 2 is enrolling, and CEO Blair Jackson framed the ADHD plus sleep pipeline as a potential first blockbuster for the company.
Bayer sold Stivarga to Grünenthal for up to EUR 375 million. The Grünenthal release, dated September 21 from Aachen, covers regorafenib in metastatic colorectal cancer, GIST, and liver cancer, projects roughly EUR 100 million of 2027 EBITDA contribution, and anticipates loss of exclusivity in 2029 in the EU and 2030 in the US. Close is expected end 2026 or early 2027.
The IPO queue grew. TRex Bio, a Treg biology company with Lilly having indicated interest in participating, filed its S-1 on September 18 with TRB-061, a TNFR2 agonist in atopic dermatitis, leading the pipeline. Retension Pharmaceuticals, developing RTN-001 for uncontrolled hypertension, filed September 20 with $13.5 million of June 30 cash. Neither named terms, per Fierce Biotech from the filings. Both price into the window Electra just stress tested.
Mayo Clinic and Thermo Fisher formed Precure. The venture, majority owned by Mayo, aims to build a population scale molecular dataset from one million biospecimens, with Regeneron funding a prospective study of up to 100,000 participants, per MedTech Dive dated September 21.
Also Monday: Johnson & Johnson said Caplyta hit in one of two Phase 3 studies in bipolar disorder associated manic episodes (Fierce Pharma). PTC Therapeutics completed its acquisition of the ST-920 Fabry disease gene therapy, on the wire at 4:30 pm ET. Eli Lilly broke ground on a Houston manufacturing site it called one of ten US sites announced since 2020, on the wire at 5:40 pm ET. The Pentagon defended designating WuXi AppTec a Chinese military company (Endpoints News). Fierce Biotech reported China’s new five year plan targets a 25% share of global first in class drugs. And Fierce Pharma reported the President teased splitting some childhood vaccines into smaller doses; no regulatory action accompanied the remarks.
How did the tracked tape close on Monday, September 21?
Grail led the tape into panel week, Telix and Novo absorbed the session’s two big markdowns, and two of our tracked round trip lines finally broke to the upside. All closes are exchange closes, and all percentage moves are our arithmetic from those closes.
| Ticker | Monday close | Move vs Friday | Note |
|---|---|---|---|
| GRAL | $107.97 | +33.7% | From $80.77; briefing documents posted; panel Wednesday |
| TLX | $11.31 | −10.2% | Nasdaq listed shares; equity consideration struck at US$11.841 |
| NVO | $39.80 | −8.0% | ADRs; Capital Markets Day session |
| XENE | $38.99 | −1.9% | Session two after the 30.7% plunge; stabilization, not recovery |
| ETRA | $13.92 | +5.1% | Session two; still 7.2% below the $15.00 issue price; deal closed Monday, greenshoe clock day one |
| SRRK | $48.16 | +3.2% | Five session post approval slide broken |
| BHVN | $14.22 | +4.4% | Thursday’s +15.6% remains unexplained; no disclosure found Monday night |
| DFTX | $39.28 | +1.2% | First close above the $38.89 round trip line |
| VERA | $34.25 | +0.7% | Back above the $34.05 line |
| SION | $6.00 | +0.7% | No cause for Friday’s 17.0% drop has surfaced; scope: Monday night sweeps |
| RARE | $14.65 | +1.0% | Fayuvi pricing document still unpublished |
| SMMT | $16.90 | −5.3% | No news found; no cause assigned; ivonescimab decision November 14 |
| IONS | $44.90 | +1.0% | |
| AMGN | $393.16 | +1.9% | |
| AMLX | $32.39 | −0.1% |
How is deadline gauntlet week tracking?
Four dated disclosures anchor this week and next, and the first one just delivered its document a day inside the historical window. Friday’s edition grades the full slate; here is the scoreboard at the Tuesday mark.
| Date | Event | Status at Tuesday |
|---|---|---|
| Sept 23 (Wed) | Grail Galleri advisory committee, first MCED PMA panel | Briefing documents posted Monday per Reuters, STAT, and Endpoints; panel meets Wednesday; vote count in Thursday’s edition |
| Sept 25 (Fri) | AbbVie full CERVINO etentamig data | Pending; the withheld medians come due |
| Sept 29 (Mon) | Section 232 pharmaceutical tariffs | Pending; MFN participants were promised tariff relief per The Hill via Fierce Healthcare |
| Sept 30 (Tue) | GENEROUS Medicaid MFN signing deadline; GSK flu Phase 3 window closes | 40 states plus Puerto Rico signed per CMS; GSK start still unannounced as of Monday night |
Frequently asked questions
When is the FDA advisory committee meeting for Grail’s Galleri test?
Wednesday, September 23, 2026, from 9:00 am to 6:00 pm ET, before the Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee at FDA’s White Oak campus, with a public YouTube webcast. The docket number is FDA-2026-N-8004.
What will the Galleri panel vote on?
Per Endpoints News, the committee is expected to vote on the safety and benefit of Galleri as part of FDA’s review of the first premarket approval application for a multi cancer early detection test. The FDA is not bound by the vote.
Did the FDA recommend approving Galleri?
No. The briefing documents do not make an approval recommendation. Per Reuters, FDA staff said they had no outstanding questions for the panel on analytical performance, study design, or primary safety, and asked the panel to discuss the “early detection” characterization.
Why did Grail stock jump 33.7% on Monday?
Shares closed at $107.97 against Friday’s $80.77 after the briefing documents posted and multiple outlets characterized them as free of major FDA concerns. The percentage is our arithmetic from those two exchange closes.
What is Galleri and is it available today?
Galleri is Grail’s blood based multi cancer early detection test. It is sold today as a laboratory developed test without FDA approval and generated $136.8 million in US revenue in 2025, per Reuters. FDA approval would support broader reimbursement.
How much is Telix paying for ITM?
US$1.65 billion upfront on a cash free, debt free basis, comprising US$1.25 billion in Telix shares at US$11.841 per share, US$302 million of assumed net debt, and US$96 million of management rollover and expenses, plus up to US$700 million in contingent milestones.
What is ITM-11?
ITM-11 is 177Lu-edotreotide, a radioligand therapy for gastroenteropancreatic neuroendocrine tumors. COMPETE, its first Phase 3, is complete; COMPOSE is fully enrolled with an interim analysis expected in the first half of 2027. It is under FDA review and would compete with Novartis’ Lutathera.
Why does ITM’s lutetium-177 business matter?
ITM is the only producer of globally scaled commercial grade lutetium-177 and holds 15 year exclusive access to Bruce Power’s reactors in Canada, per the release. That supply position underpins radioligand manufacturing across the industry, including for competitors.
When does the Telix ITM deal close?
The companies expect closing by the end of 2026, subject to Telix shareholder approval at an extraordinary general meeting expected in November 2026 and regulatory clearances.
What sales target did Novo Nordisk set at its Capital Markets Day?
At least five multi blockbusters by 2030, with combined sales above DKK 150 billion in less than 10 years, a figure CEO Mike Doustdar described as risk adjusted. The figures are company statements reported by Fierce Pharma.
What is the GENEROUS model and what happens September 30?
GENEROUS is a five year CMS model letting state Medicaid programs buy hundreds of drugs at most favored nation aligned prices. CMS said 40 states plus Puerto Rico have signed agreements and the remaining states have until September 30.
What did IntraBio’s Aqneursa get approved for?
The FDA expanded Aqneursa into ataxia-telangiectasia, the first approved treatment for the disease, based on the Phase 3 IB1001-303 crossover study in 73 patients showing close to a 2 point SARA improvement, per Fierce Pharma.
What did Beacon Therapeutics report in X-linked retinitis pigmentosa?
In the pivotal VISTA study, 24.1% of low dose and 31% of high dose laru zova patients gained 15 or more letters of low light visual acuity at 12 months versus 0% of controls, and Beacon plans to complete a rolling BLA by year end 2026.
Which biotechs filed to go public after Electra’s IPO?
TRex Bio filed its S-1 on September 18 and Retension Pharmaceuticals on September 20, both for Nasdaq listings without terms named. Electra, the year’s 21st biotech IPO, closed its deal Monday with shares 7.2% below the $15.00 issue price.
Sources
Primary sources: Telix and ITM merger release, September 21, 2026, via BioSpace press release carry. Grünenthal Stivarga acquisition release, September 21, 2026, Aachen, via PR Newswire. FDA advisory committee meeting page for the September 23, 2026 Molecular and Clinical Genetics Panel (meeting logistics, webcast, docket FDA-2026-N-8004), fetched September 21. CMS GENEROUS model announcement as reported September 21. Exchange closes for all tickers, September 18 and September 21, 2026.
Trade press and wires, September 20 to 21, 2026: Reuters (Grail briefing documents, wire carry). STAT News (Grail documents; Telix ITM deal context). Endpoints News (Grail adcomm; Pfizer and Lilly MFN contract details; WuXi AppTec). Fierce Biotech (Telix ITM terms breakdown; Cue Biopharma CUE-221; Alkermes ALKS 7290; Beacon VISTA; TRex and Retension filings; China five year plan). Fierce Pharma (Novo Capital Markets Day; IntraBio Aqneursa; J&J Caplyta; childhood vaccine remarks). Fierce Healthcare (GENEROUS model, citing The Hill). MedTech Dive (Mayo Clinic and Thermo Fisher Precure, dated September 21). StockTitan wire timestamps (PTC ST-920 completion 4:30 pm ET; Lilly Houston 5:40 pm ET).
Related coverage
- Xenon fell 30.7% after pausing two depression trials as Electra closed 11.7% below its IPO price and Grail’s panel neared with no briefing documents (September 21, 2026)
- The FDA approved Ultragenyx’s Fayuvi two days early as Bayer’s Kerendia won the first type 1 diabetes CKD nod in over 30 years (September 18, 2026)
- Vera’s Trutakna cut kidney disease progression risk 76% over two years (September 17, 2026)
- Scholar Rock’s Isembyld won FDA approval 19 days early (September 15, 2026)
